Peptide Comparison
CrystagenvsThymosin Alpha-1
Immunogeroprotective tripeptide bioregulator (Glu-Asp-Pro) that optimally stimulates thymic epithelial cell proliferation at 200 ng/mL, suppresses thymocyte apoptosis through p53 downregulation and Ki-67 upregulation, and contributed to a 4.1-fold mortality reduction in a 266-person 6-8 year clinical study when combined with complementary pineal peptides
Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age.
At a Glance
Quick
comparison
Dose Range
Crystagen
1–100 mcg/kg
Thymosin Alpha-1
1.6–3.2 mg
Frequency
Crystagen
Once daily
Thymosin Alpha-1
Twice weekly
Administration
Crystagen
Subcutaneous injection
Thymosin Alpha-1
Subcutaneous injection
Cycle Length
Crystagen
8-12 weeks
Thymosin Alpha-1
8-12 weeks
Onset Speed
Crystagen
Gradual (3-4 weeks)
Thymosin Alpha-1
Moderate (1-2 weeks)
Evidence Level
Crystagen
Limited human trials
Thymosin Alpha-1
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Immune Rejuvenation
Healthy Aging
Cancer Defense
Immune Activation
Infection Fighting
Immune Balance
Technical Data
Compound
specifications
Crystagen
Molecular Formula
C14H21N3O8
Molecular Weight
359.3 g/mol
Half-Life
Short plasma half-life typical of tripeptides (minutes); biological effects persist for weeks to months through gene expression modifications and thymic microenvironment restoration; metabolized to constituent amino acids
Bioavailability
Absorbed via intestinal peptide transporters (PepT1/POT and LAT carrier families) when administered orally; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to ultra-short tripeptide structure
CAS Number
Not assigned (patented as immunogeroprotective peptide, US8057810B2)
Thymosin Alpha-1
Molecular Formula
C129H215N33O55
Molecular Weight
3108.32 g/mol
Half-Life
Approximately 2 hours
Bioavailability
High when injected subcutaneously (rapid absorption, peak at ~2 hours)
CAS Number
62304-98-7
Protocols
Dosing
tiers
Crystagen
Thymosin Alpha-1
Applications
Best
suited for
Crystagen
Restoring thymic function and immune competence in aging individuals with immune senescence
Crystagen is particularly well-suited for individuals focused on restoring thymic function and immune competence in aging individuals with immune senescence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols for immune and anti-aging support
Crystagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for immune and anti-aging support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting immune function during and after illness recovery
Crystagen is particularly well-suited for individuals focused on supporting immune function during and after illness recovery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence
Crystagen is particularly well-suited for individuals focused on geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymosin Alpha-1
Chronic Hepatitis B or C Support
Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment.
Cancer Treatment Support
When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments.
Age-Related Immune Decline
As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time.
Severe Infection Recovery
In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability.
Safety Profile
Side
effects
Crystagen
Common
- Injection site reaction
- Mild fatigue
- Mild headache
- Minor digestive changes
Uncommon
- Flu-like symptoms
Serious
- No documented serious adverse effects
Thymosin Alpha-1
Common
- Injection site reactions
- Mild fatigue
- Flu-like symptoms
Uncommon
- Mild fever
- Lymph node awareness
Serious
- Allergic reaction
Research Status
Safety
& evidence
Crystagen
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
Crystagen is a crystalline protein extract (likely containing collagen-derived peptides) from animal tissues that is not FDA-approved and has essentially no published safety data in medical literature. As an undefined and poorly characterized biological mixture, batch consistency, sterility, and identity cannot be verified. Potential risks include allergic reactions to animal proteins, contamination from source tissues, and unknown immunological effects. No formal safety assessments, animal studies, toxicology screening, or human clinical trials exist. The product appears to exist primarily in Russian medical markets, and little information about its actual composition or manufacturing is publicly available.
Contraindications
- xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, proline)
- xPregnancy and breastfeeding — insufficient reproductive safety data
- xActive autoimmune disease in flare without physician supervision
- xOrgan transplant recipients on immunosuppression — potential interference with immunosuppressive regimens
Thymosin Alpha-1
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
FDA approved for other use
Safety Overview
Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions.
Contraindications
- xOrgan transplant recipients on immunosuppressants
- xActive autoimmune disease flares
- xKnown allergy to thymosin peptides
- xPregnancy or breastfeeding
- xChildren under 18 without medical supervision
Decision Guide
Which is
right for you?
Choose Crystagen if...
- Restoring thymic function and immune competence in aging individuals with immune senescence
- Comprehensive Khavinson bioregulator protocols for immune and anti-aging support
- Supporting immune function during and after illness recovery
- Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence
Choose Thymosin Alpha-1 if...
- Immune system strengthening
- Chronic infection support
- Cancer adjunct therapy
- Healthy aging immune support